Q2 2023 EPS Estimates for Mustang Bio, Inc. Increased by HC Wainwright (NASDAQ:MBIO)

Mustang Bio, Inc. (NASDAQ:MBIO – Get Rating) – Research analysts at HC Wainwright increased their Q2 2023 EPS estimates for shares of Mustang Bio in a research report issued to clients and investors on Tuesday, May 23rd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($1.71) for the quarter, up from their prior forecast of ($2.14). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Mustang Bio’s current full-year earnings is ($7.55) per share. HC Wainwright also issued estimates for Mustang Bio’s Q3 2023 earnings at ($1.54) EPS, Q4 2023 earnings at ($1.68) EPS and FY2023 earnings at ($6.98) EPS.

Mustang Bio Stock Up 2.9 %

MBIO stock opened at $5.02 on Thursday. The firm has a 50 day moving average of $4.41 and a 200 day moving average of $6.63. The stock has a market capitalization of $40.96 million, a PE ratio of -0.48 and a beta of 1.86. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of 0.93. Mustang Bio has a 52 week low of $2.82 and a 52 week high of $14.10.

Institutional Trading of Mustang Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Mustang Bio during the 4th quarter valued at approximately $56,000. HighTower Advisors LLC acquired a new stake in Mustang Bio during the 4th quarter valued at approximately $115,000. Spotlight Asset Group Inc. acquired a new stake in Mustang Bio during the 3rd quarter valued at approximately $138,000. Vanguard Group Inc. lifted its stake in Mustang Bio by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,666,959 shares of the company’s stock valued at $1,252,000 after acquiring an additional 482,361 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in Mustang Bio by 168.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 120,980 shares of the company’s stock valued at $57,000 after acquiring an additional 75,996 shares during the period. 13.66% of the stock is currently owned by institutional investors and hedge funds.

About Mustang Bio

(Get Rating)

Mustang Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders.